SHEILA QUINN: Open Payments
NPI 1700036506 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,631 in 90 payments from 15 companies in 2025. Trend: 2023 $477 · 2024 $1,078 · 2025 $1,631
Food & beverage: $1,631
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $524 |
| Janssen Biotech, Inc. | 19 | $257 |
| Lilly USA, LLC | 12 | $255 |
| UCB, Inc. | 15 | $217 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Biofrontera Inc. | 1 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| GENZYME CORPORATION | 2 | $43 |
| Amgen Inc. | 2 | $31 |
| Incyte Corporation | 1 | $28 |
Products named: TREMFYA, Bimzelx, BOTOX, SKYRIZI, TALTZ, EBGLYSS, DUPIXENT, RINVOQ.
Industry payments across NV — which companies pay providers there.
